View ACRP-CP Exam Question Dumps With Latest Demo [Dec 05, 2025]
Free ACRP-CP Test Questions Real Practice Test Questions
NEW QUESTION # 12
The IRB/IEC has decided to not approve a clinical trial. Who must they notify in writing?
- A. CRC
- B. Regulatory Agency
- C. Sponsor
- D. PI
Answer: D
Explanation:
When the IRB/IEC decides not to approve a clinical trial, they must notify the Principal Investigator (PI) in writing. This communication ensures that the PI is formally informed of the decision and cantake appropriate actions, such as revising the protocol or addressing the reasons for disapproval.
According to GCP guidelines, the IRB/IEC must communicate any decision regarding the approval status of a study directly to the PI, as the PI is responsible for the conduct of the trial.
"The IRB/IEC should promptly notify the investigator in writing of its decision to approve or disapprove the proposed research activity." Objectives:
* Maintain clear communication between the IRB/IEC and the investigator.
* Ensure timely notification of decisions affecting the study.
NEW QUESTION # 13
Which of the following statements is TRUE about an EDC system?
- A. IRB/IEC approval is required before the use of the computerized system.
- B. There should be an audit trail to track data entries, deletions, and changes.
- C. A separate workstation should be made available for the monitor.
- D. The eCRF should be an exact page-by-page replica of the paper CRF.
Answer: B
Explanation:
An Electronic Data Capture (EDC) system must include an audit trail to ensure data integrity. This audit trail records every data entry, modification, and deletion along with timestamps and user identification. It is a critical feature for maintaining traceability and accountability in clinical research, allowing for the reconstruction of data changes and ensuring compliance with Good Clinical Practice (GCP).
GCP guidelines mandate that electronic data systems used in clinical trials must maintain an audit trail to ensure data integrity and traceability.
"An audit trail is essential in an EDC system to document all data entries, changes, and deletions to maintain data integrity." Objectives:
* Ensure data integrity through traceable record-keeping.
* Maintain compliance with regulatory standards.
NEW QUESTION # 14
Who is responsible to ensure training for key staff members unable to attend the site initiation visit?
- A. Coordinator
- B. Sponsor
- C. Investigator
- D. Monitor
Answer: C
Explanation:
The Principal Investigator (PI) is responsible for ensuring that all site staff involved in the study are adequately trained, even if they were unable to attend the Site Initiation Visit (SIV). This responsibility includes organizing training sessions or providing relevant training materials to maintain consistency and compliance with study protocols.
According to GCP guidelines, the PI must ensure that all staff members involved in the trial are adequately informed and trained on their specific responsibilities.
"The investigator should ensure that all persons assisting with the trial are adequately informed about the protocol, the investigational product(s), and their trial-related duties and functions." Objectives:
* Maintain consistent training for all clinical staff.
* Ensure compliance with study procedures.
NEW QUESTION # 15
Which of the following documents is maintained by a PI to ensure compliance with sponsor requirements?
- A. A monitoring report that identifies deviation from the approved protocol.
- B. Regulatory submission of protocol and accompanying documents to relevant regulatory authority.
- C. A monitoring plan that is tailored to the specific human subject protection and data integrity risks of the trial.
- D. Training records of site personnel on study protocol, and their study-related duties and functions.
Answer: D
Explanation:
The PI is responsible for maintaining training records of site personnel, which demonstrate compliance with the sponsor's requirements for conducting the trial. Proper documentation of training ensures that all team members are knowledgeable about the protocol and study procedures.
GCP guidelines mandate that the PI maintains adequate records to demonstrate that all personnel involved in the study are properly trained and qualified.
"Training records of site personnel must be maintained to verify that the team is adequately trained on the protocol and their specific responsibilities." Objectives:
* Maintain training compliance.
* Document personnel qualifications for quality assurance.
NEW QUESTION # 16
A hospital site is being considered for a trial that requires the IP refrigerator to be continuously monitored using the sponsor-provided Wi-Fi-enabled thermometer. The hospital's Wi-Fi connectivity is inconsistent.
During site selection, how should the CRA proceed?
- A. Before accepting this site, report the risk to the trial sponsor and await their decision.
- B. Accept this site and implement and maintain QA and QC systems with written SOPs.
- C. Accept this site and plan to undertake routine safety evaluations of the IP.
- D. Before accepting this site, ensure the refrigerator is calibrated and functioning properly.
Answer: A
Explanation:
Since the Wi-Fi connectivity is inconsistent, the CRA must assess the risk and report it to the trial sponsor for a decision. Accepting the site without proper risk evaluation may compromise the monitoring of the investigational product (IP) storage conditions, affecting trial integrity.
The answer follows GCP guidelines that emphasize assessing potential risks during site selection and involving the sponsor when critical issues arise.
"When faced with site-specific issues that may affect data integrity or product safety, the CRA should consult with the sponsor before making a final decision." Objectives:
* Ensuring proper site selection
* Managing potential risks proactively
NEW QUESTION # 17
The IB contains which of the following sections?
- A. Participant dosing schedule
- B. Known pharmacokinetic effects
- C. Participant eligibility criteria
- D. IP preparation instructions
Answer: B
Explanation:
The Investigator's Brochure (IB) contains comprehensive information about the investigational product (IP), including its pharmacokinetic and pharmacodynamic properties, preclinical and clinical trial data, and any known side effects. The IB provides a scientific basis for the study protocol and helps investigators understand the potential risks and benefits.
GCP guidelines state that the IB must include relevant scientific data, including pharmacokinetic and pharmacodynamic profiles.
"The IB should provide data on the pharmacokinetics and pharmacodynamics of the investigational product to inform clinical practice." Objectives:
* Provide comprehensive data on investigational products.
* Support safe and informed clinical decision-making.
NEW QUESTION # 18
Who is responsible for securing agreement from all involved parties to ensure direct access of all trial-related source documents?
- A. CRC
- B. Sponsor
- C. CRO
- D. Investigator
Answer: B
Explanation:
The sponsor is responsible for ensuring that agreements are in place with all involved parties (including investigators and institutions) to grant direct access to trial-related source documents. This is crucial for monitoring, auditing, and inspection purposes, ensuring transparency and compliance with regulatory requirements.
According to GCP guidelines, the sponsor must establish agreements to secure direct access to trial data for verification and compliance checks.
"The sponsor should ensure that agreements are in place to permit direct access to source data and documents for monitoring and inspection." Objectives:
* Maintain compliance with regulatory requirements.
* Facilitate data verification and quality assurance.
NEW QUESTION # 19
A PI is reviewing the CRF for a recent subject visit and notices the participant's heart rate and temperature are not recorded. Which of the following study documentation practices was neglected?
- A. Original
- B. Contemporaneous
- C. Attributable
- D. Complete
Answer: D
Explanation:
The missing data indicates a lack of completeness in the study documentation. Completeness is a fundamental requirement in clinical trials, as all necessary information must be recorded accurately and in full. Missing vital signs such as heart rate and temperature can compromise the validity of the data and affect the study's outcomes.
GCP guidelines state that all data collected during the study must be complete, accurate, and consistent with source documents.
"Clinical trial documentation must be complete, containing all data as required by the protocol toensure data integrity." Objectives:
* Ensure comprehensive data recording.
* Maintain accuracy and completeness in study records.
NEW QUESTION # 20
A monitor identifies multiple deviations from a protocol-defined timeline for study procedures. The monitor is unable to identify proof of PI review and assessment of the deviations. The monitor discusses the deviations with the PI, who initiates a CAPA. What is the purpose of this CAPA?
- A. To determine if a protocol amendment is needed
- B. To escalate corrective actions to the regulatory authority
- C. To determine if the deviations invalidate the data
- D. To establish a procedure for PI oversight of protocol deviations
Answer: D
Explanation:
A Corrective and Preventive Action (CAPA) plan is implemented to address deviations and prevent them from recurring. In this context, the purpose of the CAPA is to establish a procedure for the Principal Investigator (PI) to ensure proper oversight of protocol deviations. This ensures that all future deviations are appropriately managed, reviewed, and documented according to GCP standards.
The answer is verified from GCP guidelines which emphasize that CAPA should focus on identifying root causes and establishing processes to prevent future deviations.
"A CAPA plan must address the root cause and implement systematic actions to prevent the recurrence of protocol deviations." Objectives:
* Ensuring PI oversight in protocol adherence
* Maintaining data integrity through systematic corrective actions
NEW QUESTION # 21
Who takes responsibility for initiating a clinical trial?
- A. Sponsor
- B. CRO
- C. IRB/IEC
- D. Investigator
Answer: A
Explanation:
The sponsor is responsible for initiating a clinical trial. This involves developing the protocol, securing funding, selecting study sites, and obtaining regulatory approvals. The sponsor also oversees the conduct of the trial to ensure compliance with GCP and regulatory requirements.
According to GCP guidelines, the sponsor is the entity that initiates, manages, and finances the clinical investigation.
"The sponsor is responsible for initiating, managing, and financing the clinical trial, including protocol development and site selection." Objectives:
* Understand the sponsor's role in trial initiation.
* Ensure compliance from the outset of the study.
NEW QUESTION # 22
While reviewing reports of data completion, the sponsor notices low retention rates at many participating sites. What is an appropriate FIRST action for the sponsor to take?
- A. Meet with the site staff to understand their workflows and to review retention strategies.
- B. Require participants to provide documented reason for withdrawal.
- C. Submit revised ICFs to the IRB/IEC with increased compensation for participants.
- D. Interview participants who have dropped out.
Answer: A
Explanation:
Meeting with site staff to understand workflows and retention strategies is the most practical first step. By engaging with the team, the sponsor can identify potential issues affecting retention, such as site-related factors, participant burden, or protocol complexities. Addressing these issues collaboratively can improve retention without needing major protocol changes.
GCP guidelines recommend assessing and understanding site-specific challenges before making procedural changes or protocol amendments.
"Engaging with site staff to discuss retention issues helps identify root causes and develop practical solutions." Objectives:
* Improve participant retention through collaboration.
* Identify and address site-specific challenges.
NEW QUESTION # 23
A clinical trial is conducted to measure the effectiveness of music therapy to reduce anxiety in intensive care unit patients. Patients are randomly assigned to receive headphones with music of their choice or headphones with white noise. The group receiving the white noise headphones is considered which type of control group?
- A. Placebo
- B. Active control
- C. No treatment
- D. Alternate dose
Answer: A
Explanation:
In this trial, the white noise group acts as a placebo control. While they are receiving an intervention (white noise), it is not the active therapeutic intervention (music therapy) being tested. Placebo controls help in assessing the effect of the active intervention by comparing it to a neutral or non-therapeutic alternative.
GCP guidelines state that a placebo control is a neutral intervention used to compare the effects of an active treatment.
"A placebo group is one that receives a neutral intervention, used to measure the efficacy of the active intervention by comparison." Objectives:
* Differentiate between active and placebo control groups.
* Evaluate therapeutic efficacy objectively.
NEW QUESTION # 24
Per the protocol, participants' blood creatinine level must be no greater than 2.5 times the upper limit of normal (0.7-1.2 mg/dL). What is the maximum creatinine level the participant can have and be eligible for the trial?
- A. 3.6 mg/dL
- B. 2.6 mg/dL
- C. 3.0 mg/dL
- D. 1.8 mg/dL
Answer: C
Explanation:
To calculate the maximum allowable creatinine level, multiply the upper limit of normal (1.2 mg/dL) by 2.5.
1.2 x 2.5 = 3.0 mg/dL
Therefore, the maximum creatinine level that a participant can have to remain eligible for the trial is 3.0 mg
/dL.
GCP guidelines specify that eligibility criteria, including lab values, must be strictly followed to maintain protocol compliance.
"The protocol specifies that laboratory values must not exceed the defined limits to ensure participant safety and data integrity." Objectives:
* Maintain accurate interpretation of laboratory criteria.
* Ensure compliance with protocol-defined inclusion/exclusion criteria.
NEW QUESTION # 25
A site has reported multiple temperature excursions for an IP, primarily because the air conditioning (A/C) gets shut off after business hours. A separate A/C unit cannot be installed in the room where the IP is kept.
What would be the MOST effective long-term mitigation strategy?
- A. Return all IP and request the CRO/Sponsor to directly ship IP to participants.
- B. Continue reporting temperature excursions per the pharmacy manual guidelines.
- C. Invest in a room temperature controlled IP cabinet and transfer IP to this unit.
- D. Install an air cooler requiring regular water refills to maintain the room temperature.
Answer: C
Explanation:
Investing in a temperature-controlled IP cabinet is the most effective and sustainable solution for maintaining IP stability. This cabinet can consistently regulate temperature without relying on external A/C systems, thereby minimizing the risk of excursions and ensuring compliance with storage requirements.
GCP guidelines state that IP must be stored under controlled conditions as specified by the protocol and product labeling.
"Temperature-controlled storage units should be used when site environmental conditions are not reliable to maintain IP stability." Objectives:
* Ensure IP stability and compliance.
* Mitigate temperature excursion risks effectively.
NEW QUESTION # 26
Which statement does NOT represent a study monitor's responsibilities?
- A. Provide communication between the sponsor and the PI.
- B. Check the accuracy and completeness of case report forms with source documents.
- C. Verify that the PI has adequate qualifications and resources to conduct the study.
- D. Report serious adverse events to the IRB/IEC.
Answer: D
Explanation:
It is not the monitor's responsibility to report serious adverse events (SAEs) to the IRB/IEC. This responsibility typically falls on the PI or the sponsor. Monitors focus on data accuracy, protocol compliance, and communication between the site and the sponsor.
The answer follows GCP standards where the monitor's role is clearly defined, excluding SAE reporting to IRB/IEC.
"Monitors are responsible for verifying data accuracy and communicating with the sponsor but not for direct reporting of SAEs to the IRB/IEC." Objectives:
* Distinguish between the responsibilities of monitors and investigators
* Clarify SAE reporting protocols
NEW QUESTION # 27
An audit was recently completed and identified non-compliance that could potentially affect the reliability of study results. Who should perform a root cause analysis and implement appropriatecorrective and preventive actions?
- A. Sponsor
- B. PI
- C. DSMB/IDMC
- D. IRB/IEC
Answer: B
Explanation:
The Principal Investigator (PI) is responsible for conducting a root cause analysis when non-compliance is identified at the site. The PI must identify the reasons for non-compliance and develop a Corrective and Preventive Action (CAPA) plan to address and prevent future occurrences.
This answer aligns with GCP principles that designate the PI as responsible for site-level compliance and corrective actions.
"The PI must take responsibility for investigating the cause of non-compliance and developing a CAPA plan to mitigate recurrence." Objectives:
* Maintaining compliance and data integrity
* Addressing non-compliance proactively
NEW QUESTION # 28
......
View All ACRP-CP Actual Free Exam Questions Updated: https://prep4sure.dumpsfree.com/ACRP-CP-valid-exam.html